注射用灯盏花素治疗不稳定性心绞痛合并高脂血症临床观察
|
摘要
目的：本课题通过观察两组不稳性心绞痛合并高脂血症患者治疗前后全血黏度、血脂、心绞痛发作次数、心电图的变化,并监测治疗前后两组粪便常规、尿常规、血常规及肝肾功能的变化,来探讨注射用灯盏花素对不稳定性心绞痛合并高脂血症患者的临床疗效及安全性,同时为今后临床中西结合治疗冠心病不稳定性心绞痛提供一定的参考。
材料与方法：选择武汉市普爱医院2009年5月至2010年5月收治的不稳定性心绞痛合并高脂血症患者62例,所有病例均符合2003年中华心血管病杂志编辑委员会《心血管病指南和建议》中不稳定性心绞痛及血脂异常诊断标准,随机分为治疗组30例和对照组32例,治疗组男16例,女14例,年龄45～72岁,平均年龄60±5.77岁,合并高血压14例,糖尿病10例,陈旧性心肌梗死3例,合并糖耐量异常3例；对照组男17例,女15例,年龄44～70岁；平均年龄58±7.50岁,合并高血压16例,糖尿病9例,陈旧性心肌梗死5例,糖耐量异常2例,两组性别、年龄、病程、合并症等方面比较差异无统计学意义(P>0.05),具有可比性。两组患者均予不稳定性心绞痛的常规西医治疗及其他治疗如降压、降糖等。治疗组在以上基础上给予灯盏花素注射液50mg加入0.9%氯化钠250ml静脉滴注,每天1次,连用两周。治疗期间进行生活方式的干预,如戒烟酒、避免过饱、过劳、情绪激动等。记录两组治疗前后全血黏度、血脂、心绞痛发作次数、心电图ST-T变化情况,以治疗前后粪便常规、尿常规、血常规、肝功能、肾功能作为安全性观察指标。
结果：治疗组心绞痛症状缓解显效12例(40%),有效14例(46.7%),无效4例(13.33%),加重为0例,总有效率为86.67%；对照组显效9例(28.13%),有效15例(46.88%),无效8例(25%),加重0例,总有效率为75%,明显低于治疗组,两者比较有统计学意义(P<0.05)。心电图的变化治疗组显效16例(53.33%),有效9例(30%),无效5例(16.67%),加重0例,总有效率83.33%；对照组显效8例(25%),有效13例(40.63%),无效11例(34.38%),总有效率为65.63%,两者比较有统计学意义(P<0.05)。两组治疗前后血黏度及血脂变化比较,差异有统计学意义(P<0.05)。治疗组心绞痛发作次数及程度明显低于对照组,差异有统计学意义(P<0.05)。两组治疗前后粪便常规、尿常规、血常规、肝功能、肾功能的变化,经计算差异无统计学意义(P>0.05)。
结论：21世纪,冠心病是人类最常见的死亡原因之一,不单在经济发达的国家如此,发展中国家以及欠发达国家亦如是,冠心病已成为一个影响人类生存生活的重大公共卫生问题,因此防治冠心病,降低冠心病死亡率显得极为重要。注射用灯盏花素能降低冠心病不稳定性心绞痛患者全血黏度、血脂,扩张冠脉改善微循环从而减少心绞痛发作次数,且安全无不良反应,可作为不稳定性心绞痛治疗的药物。
Objective:This topic was to observe the injectable lamps spend grain to merge unstable angina patients with hyperlipidemia, and to find the clinical curative effect for future clinical treatment of coronary heart disease combined with western routine provide method and maybe certain reference by recording the whole blood viscosity, blood fat and anginal attacks, ECG changes before and after the treatment, and monitor stool, urine, blood routine examination, liver and kidney function changes of the between two groups.
Materials and methods:Sixty-two cases of merge unstable angina patients with hyperlipidemia from Puai hospital in wuhan city from May 2009 to May 2010 were selected. All cases followed 2003 cardiovascular magazine editors committee "cardiovascular disease" guidelines and suggestions of unstable angina and hyperlipidemia diagnosis criteria.62 cases were randomly divided into the treatment group 30 cases and control group 32 cases. The treatment group consists of male 16 cases, female 14 cases, age range from 45-72, with an average age of 60±5.77 years old,14 cases with amalgamating hypertension,10 cases with diabetes,3 cases with chronic myocardial infarction,3 cases with abnormal glucose tolerance; The control group male 17cases, female 15 cases, age 44-70 years old; with average age 58±7.50 years old,16 cases with amalgamating hypertension,9cases with diabetes,5 cases with chronic myocardial 3 cases with abnormal glucose tolerance, no significant.difference was found in gender, age, duration, and complications between 2 groups (P> 0.05), patients of 2 groups were given western medicine therapy to unstable angina and other treatments such as buck, hypoglycemic, etc. The treatment group give lamps spend grain injection 50mg join 0.9% sodium chloride 250ml intravenous drip per day by two weeks. The control group was simply received routine medicine. During treatment for lifestyle interventions, such as giving up smoking and avoiding eating too much, wine, emotional overwork. Whole blood viscosity, blood fat, anginal attacks and the amount of nitroglycerin usage, electrocardiogram ST-T change were observed before and after the treatment. Stool, urine, blood routine examination, liver and kidney function, before and after treatment were observed as safety index.
Results:Whole blood viscosity, blood fat, anginal attacks, and ECG changes before and after the treatment were monitored in the 62 cases with unstable angina and hyperlipemia group. In treatment,12 total effective cases (40%), 14 effective cases (46.7%),4 invalid cases (13.33%),0 aggravated cases, the total effective rate was 86.67%; In control,9 total effective cases, (28.13%), 15 effective cases (46.88%),8 invalid cases (25%),0 aggravated cases, the total effective rate was 75%, there were significant difference between the two goups (P< 0.05). As ECG changes, was concerned in treatment group,16 total effective (53.33%),9 effective cases (30%),5 invalid cases (16.67%),0 aggravated cases, the total effective rate was 83.33%; In control group,8 total effective cases (25%),13 effective (40.63%),11 invalid cases (34.38%), the total effective rate was 65.63%, there was of statistically differences(P< 0.05). Blood viscosity and lipid changes anginal attacks were significantly different between the two groups in treatment group(P< 0.05). There were of no significant differences in urine and stool routine analysis, liver and kidney function changes before and after the treatment (P> 0.05).
Conclusion:In 21th century, coronary heart disease has become one of the most common causes of human death, not only in the developed countries, but also in the developing countries. It has become a major public health problem. The injectable lamps spend grain can reduce patients whole blood viscosity, blood fat and expanding coronary artery, improve microcirculation thus decrease anginal attacks, and it is safe and of no obvious adverse drug reaction.
材料与方法：选择武汉市普爱医院2009年5月至2010年5月收治的不稳定性心绞痛合并高脂血症患者62例,所有病例均符合2003年中华心血管病杂志编辑委员会《心血管病指南和建议》中不稳定性心绞痛及血脂异常诊断标准,随机分为治疗组30例和对照组32例,治疗组男16例,女14例,年龄45～72岁,平均年龄60±5.77岁,合并高血压14例,糖尿病10例,陈旧性心肌梗死3例,合并糖耐量异常3例；对照组男17例,女15例,年龄44～70岁；平均年龄58±7.50岁,合并高血压16例,糖尿病9例,陈旧性心肌梗死5例,糖耐量异常2例,两组性别、年龄、病程、合并症等方面比较差异无统计学意义(P>0.05),具有可比性。两组患者均予不稳定性心绞痛的常规西医治疗及其他治疗如降压、降糖等。治疗组在以上基础上给予灯盏花素注射液50mg加入0.9%氯化钠250ml静脉滴注,每天1次,连用两周。治疗期间进行生活方式的干预,如戒烟酒、避免过饱、过劳、情绪激动等。记录两组治疗前后全血黏度、血脂、心绞痛发作次数、心电图ST-T变化情况,以治疗前后粪便常规、尿常规、血常规、肝功能、肾功能作为安全性观察指标。
结果：治疗组心绞痛症状缓解显效12例(40%),有效14例(46.7%),无效4例(13.33%),加重为0例,总有效率为86.67%；对照组显效9例(28.13%),有效15例(46.88%),无效8例(25%),加重0例,总有效率为75%,明显低于治疗组,两者比较有统计学意义(P<0.05)。心电图的变化治疗组显效16例(53.33%),有效9例(30%),无效5例(16.67%),加重0例,总有效率83.33%；对照组显效8例(25%),有效13例(40.63%),无效11例(34.38%),总有效率为65.63%,两者比较有统计学意义(P<0.05)。两组治疗前后血黏度及血脂变化比较,差异有统计学意义(P<0.05)。治疗组心绞痛发作次数及程度明显低于对照组,差异有统计学意义(P<0.05)。两组治疗前后粪便常规、尿常规、血常规、肝功能、肾功能的变化,经计算差异无统计学意义(P>0.05)。
结论：21世纪,冠心病是人类最常见的死亡原因之一,不单在经济发达的国家如此,发展中国家以及欠发达国家亦如是,冠心病已成为一个影响人类生存生活的重大公共卫生问题,因此防治冠心病,降低冠心病死亡率显得极为重要。注射用灯盏花素能降低冠心病不稳定性心绞痛患者全血黏度、血脂,扩张冠脉改善微循环从而减少心绞痛发作次数,且安全无不良反应,可作为不稳定性心绞痛治疗的药物。
Objective:This topic was to observe the injectable lamps spend grain to merge unstable angina patients with hyperlipidemia, and to find the clinical curative effect for future clinical treatment of coronary heart disease combined with western routine provide method and maybe certain reference by recording the whole blood viscosity, blood fat and anginal attacks, ECG changes before and after the treatment, and monitor stool, urine, blood routine examination, liver and kidney function changes of the between two groups.
Materials and methods:Sixty-two cases of merge unstable angina patients with hyperlipidemia from Puai hospital in wuhan city from May 2009 to May 2010 were selected. All cases followed 2003 cardiovascular magazine editors committee "cardiovascular disease" guidelines and suggestions of unstable angina and hyperlipidemia diagnosis criteria.62 cases were randomly divided into the treatment group 30 cases and control group 32 cases. The treatment group consists of male 16 cases, female 14 cases, age range from 45-72, with an average age of 60±5.77 years old,14 cases with amalgamating hypertension,10 cases with diabetes,3 cases with chronic myocardial infarction,3 cases with abnormal glucose tolerance; The control group male 17cases, female 15 cases, age 44-70 years old; with average age 58±7.50 years old,16 cases with amalgamating hypertension,9cases with diabetes,5 cases with chronic myocardial 3 cases with abnormal glucose tolerance, no significant.difference was found in gender, age, duration, and complications between 2 groups (P> 0.05), patients of 2 groups were given western medicine therapy to unstable angina and other treatments such as buck, hypoglycemic, etc. The treatment group give lamps spend grain injection 50mg join 0.9% sodium chloride 250ml intravenous drip per day by two weeks. The control group was simply received routine medicine. During treatment for lifestyle interventions, such as giving up smoking and avoiding eating too much, wine, emotional overwork. Whole blood viscosity, blood fat, anginal attacks and the amount of nitroglycerin usage, electrocardiogram ST-T change were observed before and after the treatment. Stool, urine, blood routine examination, liver and kidney function, before and after treatment were observed as safety index.
Results:Whole blood viscosity, blood fat, anginal attacks, and ECG changes before and after the treatment were monitored in the 62 cases with unstable angina and hyperlipemia group. In treatment,12 total effective cases (40%), 14 effective cases (46.7%),4 invalid cases (13.33%),0 aggravated cases, the total effective rate was 86.67%; In control,9 total effective cases, (28.13%), 15 effective cases (46.88%),8 invalid cases (25%),0 aggravated cases, the total effective rate was 75%, there were significant difference between the two goups (P< 0.05). As ECG changes, was concerned in treatment group,16 total effective (53.33%),9 effective cases (30%),5 invalid cases (16.67%),0 aggravated cases, the total effective rate was 83.33%; In control group,8 total effective cases (25%),13 effective (40.63%),11 invalid cases (34.38%), the total effective rate was 65.63%, there was of statistically differences(P< 0.05). Blood viscosity and lipid changes anginal attacks were significantly different between the two groups in treatment group(P< 0.05). There were of no significant differences in urine and stool routine analysis, liver and kidney function changes before and after the treatment (P> 0.05).
Conclusion:In 21th century, coronary heart disease has become one of the most common causes of human death, not only in the developed countries, but also in the developing countries. It has become a major public health problem. The injectable lamps spend grain can reduce patients whole blood viscosity, blood fat and expanding coronary artery, improve microcirculation thus decrease anginal attacks, and it is safe and of no obvious adverse drug reaction.
引文
[1]叶任高.内科学[M].6版.北京.人民卫生出版社,2004：272.
[2]WHO-MONICA Project:Myocardial infarction and coronary deaths in the World Health Organization Monica Project:Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Ciculation,1994(90):583.
[3]马爱群,胡大一.心血管病学[M].2005：235-304.
[4]Howard GC, Pizzo SV. Lipoprotein(a) and its role in athero-thrombotic disease[J]. LabInvestigation,1993,69:373-386.
[5]中华中医药学会内科分会心病学术专业委员会.中医心病之心绞痛诊断与疗效标准[J].中国医药学报,2004,19(10)：581-583.
[6]高润霖,吴宁,胡大一等.心血管病治疗指南和建议[M].2003：1-2.
[7]戴倩,王俊.不稳定型心绞痛治疗进展[J].疑难病杂志.2007,6(8)：505-507.
[8]王钟林.冠状动脉易损斑块的特点与临床意义[J].新医学,2004,5(9)：521-522.
[9]高方,宾建平,肖文星.不稳定型心绞痛的病因和发病机制[J].新医学,2004,35(9)：520-521.
[10]王永利,徐丁洁.不稳定型心绞痛的机制及治疗简述[J].中国医药指南,2010,8(32)：33-34.
[11]姚海华.不稳定型心绞痛的发病机制与防治进展[J].实用医学杂志, 1998,14(10)：770-772.
[12]张清,贾国良,区晋禧.冠心病患者血液脂质过氧化产物与纤溶活性的关系[J].第四军医大学学报,1996,17(2)：673-674.
[13]钟潍役,钟慧宁.不稳定型心绞痛血液流变性障碍及脉络宁的治疗作用[J].循环医学.2003,13(2)：43-44.
[14]裴志勇,杨庭树.炎症在不稳定型心绞痛发病机制中的作用[J].中国综合临床,2002,18(1)：1-3.
[15]韩梅,楚若鹏.急性冠脉综合征患者单核细胞白细胞介素-1β的表达水平及意义[J].实用医学杂志,2007,23(11)：1646-1647.
[16]黎鹏程,程丑夫,刘建和,等.冠状动脉脂质斑块中医病因病机探讨[J].中国中医药信息杂志,2008,15(9)：3-4.
[17]Nawawi H, Osman NS, Yusoff K, et al. Reduction in serum levels of adhesion molecules, interleukin 26 and C2 reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia[J]. Horm Metab Res,2003,35(8):479-485.
[18]阳军,李向平,赵水平,等.氟伐他汀早期干预对急性冠状动脉综合征患者血清炎症因子水平的影响[J].中华内科杂志,2005,44(3)：184-187.
[19]昊寿福.灯盏花注射液改善血液流变学的临床观察[J].深圳中西医结合杂志,2001,11(5)：281.
[20]石森林,徐莲英,吕圭源.灯盏花的药理学研究进展[J].浙江中医学院学报,2004,28(4)：87-89.
[21]王锦平,王永铭.灯盏花药理作用的研究[J].中成药研究,1985, 7(12)：25.
[22]许立,方泰惠,周玲玲等.灯盏花素对离体家兔心脏缺血再灌注损伤的保护作用[J].中药新药与临床约理,2005,16(6)：422-424.
[23]罗俊.不稳定心绞痛研究进展[J].心血管病学进展,2000,21(5)：302.
[24]Jia JH, Chen KP, Chen SX, et al. Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol,2008,63(6):757-762.
[25]张松,沈祥春,徐立,等.注射用灯盏花素对麻醉犬急性心肌缺血的影响[J].中药药理与临床,2004,20(2)：13-14.
[26]陆望.灯盏细辛对冠心病甲襞微循环及血液流变学的影响[J].中国煤炭医学杂志,2004,7(5)：452-453.
[27]卢惠生,罗助荣.不稳定型心绞痛CD63、CD62P、C-RP的变化及灯盏花的影响[J].心血管康复医学杂志,2001,10(5)：415.
[28]韩新玲,王永泽.中医药降脂机理初探[J].河北中医药学报,2010,25(1)：11.
[29]棘年,褚克丹.灯盖花素的药理学研究进展[J].海峡药学,2005,17(6)：5-8.
[30]Wang M, Zhang WB, Zhu JH, et al. Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Acta Pharmacol Sin.2009,30(8):81-91.
[31]盛静.灯盏细辛干预血小板凝血对急性冠状动脉血栓形成后血栓的影响[J].中华心血管杂志,1999,27：115-117.
[32]殷丽琼.灯盏细辛注射液改善微循环的临床观察[J].安徽中医临床杂志,2003,15(20)：107.
[1]马爱群,胡大一.心血管病学[M],北京：人民卫生出版社,2005,1：235-236.
[2]周仲瑛.中医内科学[M].北京：中国中医药出版社,2007：135-146.
[3]杨忠奇,冼绍祥,杜志民,等.活血化瘀法治疗冠心病(血瘀证)后行经皮冠状动脉介入的临床观察[J].新中医,2006,38(8)：42-43.
[4]葛金文,陈大舜,朱惠斌,等.血府逐瘀汤抗家兔心肌缺血作用的实验研究[J].中国医药科技,2000,70：24.
[5]杨南.益气活血汤治疗冠心病心绞痛60例分析[J].四川中医,2006,24(9)：58.
[6]冼绍祥,黄鹂,刘小虹,等.益气、行气活血法在冠心病心血瘀阻证中的治疗作用研究[J].新中医,2001,33(4)：14-16.
[7]王阶,许军,衷敬柏,等.三七总苷对高黏血症患者血小板活化分子表达和血小板聚集的影响[J].中国中西医结合杂志,2004,24(4)：312.
[8]惠学志,曲跃华,薛永亮,等.复方丹参滴丸治疗冠心病劳力型心绞痛疗效观察[J].上海中医药杂志,2003,37(5)：30-32.
[9]张龋慧,吴亚男,李宁,等.冠心苏合胶囊抗大鼠实验性血栓形成及溶栓作用[J].中草药,2006,37(4)：579-581.
[10]王向培.补肾益心片治疗冠心病不稳定性心绞痛的临床研究[D].广州：广州中医药大学,2007.
[11]徐重明,汪自源.论温通心阳法在心系病辨治中的临床应用[J].光明中医,2007,22(6)：38-40.
[12]刘静,杨市新.补肾通脉法治疗冠心病心绞痛58例疗效观[J].长春中医学院学报,2001,17(2)：24.
[13]许得盛,王文建,鲁珊妹.正心泰胶囊治疗冠状动脉粥样硬化性心脏病的临床观察[J].中国医院药学杂志,2001,21(5)：294-295.
[14]杨志刚,陈阿琴,俞颂东.三七药理研究新进展[J].上海中医药杂志, 2005,39(4)：59-61.
[15]王会玲.红花黄色素的现代研究概述[J].中国中医药科技,1998,5(5)：333-334.
[16]张润峰,李霞.丹参改善缺血再灌注血液流变学异常的作用机制[J].华西医学,2004,19(2)：341-342.
[17]王乾兰,邓秀娟,李小球,等.丹参酮注射液对不稳定型心绞痛患者CRP和D-二聚体的影响[J].新中医,2007,39(7)：16-17.
[18]戎惠玲.红花的化学成分及药理研究概况[J].江西中医学院学报,1997,9(4)：45-46.
[19]郁秀风.雷氏丹参片对冠心病合并高黏血症患者血液流变学及血脂的影响[J].中成药,2006,28(8)：1158.
[20]盛净,徐济民,扬菊贤,等.灯盏细辛对急性心肌缺血时血小板聚集率、TXB2和6-酮-PGF1α的影响[J].中华心血管病杂志,1995,23：53-55.
[2]WHO-MONICA Project:Myocardial infarction and coronary deaths in the World Health Organization Monica Project:Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Ciculation,1994(90):583.
[3]马爱群,胡大一.心血管病学[M].2005：235-304.
[4]Howard GC, Pizzo SV. Lipoprotein(a) and its role in athero-thrombotic disease[J]. LabInvestigation,1993,69:373-386.
[5]中华中医药学会内科分会心病学术专业委员会.中医心病之心绞痛诊断与疗效标准[J].中国医药学报,2004,19(10)：581-583.
[6]高润霖,吴宁,胡大一等.心血管病治疗指南和建议[M].2003：1-2.
[7]戴倩,王俊.不稳定型心绞痛治疗进展[J].疑难病杂志.2007,6(8)：505-507.
[8]王钟林.冠状动脉易损斑块的特点与临床意义[J].新医学,2004,5(9)：521-522.
[9]高方,宾建平,肖文星.不稳定型心绞痛的病因和发病机制[J].新医学,2004,35(9)：520-521.
[10]王永利,徐丁洁.不稳定型心绞痛的机制及治疗简述[J].中国医药指南,2010,8(32)：33-34.
[11]姚海华.不稳定型心绞痛的发病机制与防治进展[J].实用医学杂志, 1998,14(10)：770-772.
[12]张清,贾国良,区晋禧.冠心病患者血液脂质过氧化产物与纤溶活性的关系[J].第四军医大学学报,1996,17(2)：673-674.
[13]钟潍役,钟慧宁.不稳定型心绞痛血液流变性障碍及脉络宁的治疗作用[J].循环医学.2003,13(2)：43-44.
[14]裴志勇,杨庭树.炎症在不稳定型心绞痛发病机制中的作用[J].中国综合临床,2002,18(1)：1-3.
[15]韩梅,楚若鹏.急性冠脉综合征患者单核细胞白细胞介素-1β的表达水平及意义[J].实用医学杂志,2007,23(11)：1646-1647.
[16]黎鹏程,程丑夫,刘建和,等.冠状动脉脂质斑块中医病因病机探讨[J].中国中医药信息杂志,2008,15(9)：3-4.
[17]Nawawi H, Osman NS, Yusoff K, et al. Reduction in serum levels of adhesion molecules, interleukin 26 and C2 reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia[J]. Horm Metab Res,2003,35(8):479-485.
[18]阳军,李向平,赵水平,等.氟伐他汀早期干预对急性冠状动脉综合征患者血清炎症因子水平的影响[J].中华内科杂志,2005,44(3)：184-187.
[19]昊寿福.灯盏花注射液改善血液流变学的临床观察[J].深圳中西医结合杂志,2001,11(5)：281.
[20]石森林,徐莲英,吕圭源.灯盏花的药理学研究进展[J].浙江中医学院学报,2004,28(4)：87-89.
[21]王锦平,王永铭.灯盏花药理作用的研究[J].中成药研究,1985, 7(12)：25.
[22]许立,方泰惠,周玲玲等.灯盏花素对离体家兔心脏缺血再灌注损伤的保护作用[J].中药新药与临床约理,2005,16(6)：422-424.
[23]罗俊.不稳定心绞痛研究进展[J].心血管病学进展,2000,21(5)：302.
[24]Jia JH, Chen KP, Chen SX, et al. Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol,2008,63(6):757-762.
[25]张松,沈祥春,徐立,等.注射用灯盏花素对麻醉犬急性心肌缺血的影响[J].中药药理与临床,2004,20(2)：13-14.
[26]陆望.灯盏细辛对冠心病甲襞微循环及血液流变学的影响[J].中国煤炭医学杂志,2004,7(5)：452-453.
[27]卢惠生,罗助荣.不稳定型心绞痛CD63、CD62P、C-RP的变化及灯盏花的影响[J].心血管康复医学杂志,2001,10(5)：415.
[28]韩新玲,王永泽.中医药降脂机理初探[J].河北中医药学报,2010,25(1)：11.
[29]棘年,褚克丹.灯盖花素的药理学研究进展[J].海峡药学,2005,17(6)：5-8.
[30]Wang M, Zhang WB, Zhu JH, et al. Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Acta Pharmacol Sin.2009,30(8):81-91.
[31]盛静.灯盏细辛干预血小板凝血对急性冠状动脉血栓形成后血栓的影响[J].中华心血管杂志,1999,27：115-117.
[32]殷丽琼.灯盏细辛注射液改善微循环的临床观察[J].安徽中医临床杂志,2003,15(20)：107.
[1]马爱群,胡大一.心血管病学[M],北京：人民卫生出版社,2005,1：235-236.
[2]周仲瑛.中医内科学[M].北京：中国中医药出版社,2007：135-146.
[3]杨忠奇,冼绍祥,杜志民,等.活血化瘀法治疗冠心病(血瘀证)后行经皮冠状动脉介入的临床观察[J].新中医,2006,38(8)：42-43.
[4]葛金文,陈大舜,朱惠斌,等.血府逐瘀汤抗家兔心肌缺血作用的实验研究[J].中国医药科技,2000,70：24.
[5]杨南.益气活血汤治疗冠心病心绞痛60例分析[J].四川中医,2006,24(9)：58.
[6]冼绍祥,黄鹂,刘小虹,等.益气、行气活血法在冠心病心血瘀阻证中的治疗作用研究[J].新中医,2001,33(4)：14-16.
[7]王阶,许军,衷敬柏,等.三七总苷对高黏血症患者血小板活化分子表达和血小板聚集的影响[J].中国中西医结合杂志,2004,24(4)：312.
[8]惠学志,曲跃华,薛永亮,等.复方丹参滴丸治疗冠心病劳力型心绞痛疗效观察[J].上海中医药杂志,2003,37(5)：30-32.
[9]张龋慧,吴亚男,李宁,等.冠心苏合胶囊抗大鼠实验性血栓形成及溶栓作用[J].中草药,2006,37(4)：579-581.
[10]王向培.补肾益心片治疗冠心病不稳定性心绞痛的临床研究[D].广州：广州中医药大学,2007.
[11]徐重明,汪自源.论温通心阳法在心系病辨治中的临床应用[J].光明中医,2007,22(6)：38-40.
[12]刘静,杨市新.补肾通脉法治疗冠心病心绞痛58例疗效观[J].长春中医学院学报,2001,17(2)：24.
[13]许得盛,王文建,鲁珊妹.正心泰胶囊治疗冠状动脉粥样硬化性心脏病的临床观察[J].中国医院药学杂志,2001,21(5)：294-295.
[14]杨志刚,陈阿琴,俞颂东.三七药理研究新进展[J].上海中医药杂志, 2005,39(4)：59-61.
[15]王会玲.红花黄色素的现代研究概述[J].中国中医药科技,1998,5(5)：333-334.
[16]张润峰,李霞.丹参改善缺血再灌注血液流变学异常的作用机制[J].华西医学,2004,19(2)：341-342.
[17]王乾兰,邓秀娟,李小球,等.丹参酮注射液对不稳定型心绞痛患者CRP和D-二聚体的影响[J].新中医,2007,39(7)：16-17.
[18]戎惠玲.红花的化学成分及药理研究概况[J].江西中医学院学报,1997,9(4)：45-46.
[19]郁秀风.雷氏丹参片对冠心病合并高黏血症患者血液流变学及血脂的影响[J].中成药,2006,28(8)：1158.
[20]盛净,徐济民,扬菊贤,等.灯盏细辛对急性心肌缺血时血小板聚集率、TXB2和6-酮-PGF1α的影响[J].中华心血管病杂志,1995,23：53-55.